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Development and evaluation of a virtual
microscopy application for automated
assessment of Ki-67 expression in breast cancer
Juho Konsti1*, Mikael Lundin1, Heikki Joensuu2,3, Tiina Lehtimäki1, Harri Sihto3, Kaija Holli4,
Taina Turpeenniemi-Hujanen5, Vesa Kataja6,7, Liisa Sailas6, Jorma Isola8, Johan Lundin1,9
Abstract
Background: The aim of the study was to develop a virtual microscopy enabled method for assessment of Ki-67
expression and to study the prognostic value of the automated analysis in a comprehensive series of patients with
breast cancer.
Methods: Using a previously reported virtual microscopy platform and an open source image processing tool,
ImageJ, a method for assessment of immunohistochemically (IHC) stained area and intensity was created. A tissue
microarray (TMA) series of breast cancer specimens from 1931 patients was immunostained for Ki-67, digitized with
a whole slide scanner and uploaded to an image web server. The extent of Ki-67 staining in the tumour specimens
was assessed both visually and with the image analysis algorithm. The prognostic value of the computer vision
assessment of Ki-67 was evaluated by comparison of distant disease-free survival in patients with low, moderate or
high expression of the protein.
Results: 1648 evaluable image files from 1334 patients were analysed in less than two hours. Visual and
automated Ki-67 extent of staining assessments showed a percentage agreement of 87% and weighted kappa
value of 0.57. The hazard ratio for distant recurrence for patients with a computer determined moderate Ki-67
extent of staining was 1.77 (95% CI 1.31-2.37) and for high extent 2.34 (95% CI 1.76-3.10), compared to patients
with a low extent. In multivariate survival analyses, automated assessment of Ki-67 extent of staining was retained
as a significant prognostic factor.
Conclusions: Running high-throughput automated IHC algorithms on a virtual microscopy platform is feasible.
Comparison of visual and automated assessments of Ki-67 expression shows moderate agreement. In multivariate
survival analysis, the automated assessment of Ki-67 extent of staining is a significant and independent predictor of
outcome in breast cancer.
Background
With the emergence of virtual microscopy and whole
slide scanning techniques, there is an increasing need
for efficient tools to automate assessment of digitized
biological samples. One possible solution is to integrate
computer vision methods with a virtual microscopy plat-
form and to run the image analysis software on the
same server system as the virtual slides are stored.
A considerable number of published scientific studies
have addressed computer vision for quantification of
protein expression as determined by immunohistochem-
istry (IHC) [1-16]. Only one of the previous studies is
based on an open source solution [17]. Very few studies
have compared human visual interpretation and compu-
ter vision of IHC expression levels with regard to clini-
cally important endpoints, such as disease outcome
[2,15,16].
While tissue sample processing and IHC staining
methods are increasingly automated, the evaluation of
staining results is still predominantly performed by
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visual assessment. A human interpreter has excellent
image comprehension and pattern recognition capabil-
ities, but is prone to substantial variability in quantifica-
tion tasks. Computer vision methods are capable of
processing images consistently and generally perform
well in repetitive processes. Virtual microscopy combined
with computer vision techniques can aid the human
observer by analysis of large tissue areas at a high magni-
fication. The digital sample (i.e. the virtual slide) can be
an entire section of a single cancerous tumour or an
array of 100-200 tumour tissue samples assembled by the
use of tissue microarray technology [18].
We decided to develop and study a computer vision
method for IHC analysis that can be run on a virtual
microscopy platform and to compare the method to
visual interpretation of IHC staining. A highly studied
biomarker, Ki-67, with known prognostic value in many
cancer forms was chosen as the target [9,11,12,19-22].
Ki-67 is a protein associated with cell proliferation and
is present in all other cell cycle phases except G0, the
resting phase. Ki-67 is thoroughly studied in breast
cancer and Ki-67 immunostaining shown to be evaluable
with computer vision methods [9,11,12]. One previous
study found that semi-automated analysis of Ki-67 stain-
ing with image analysis can be used for prognostic
assessment of patients with breast cancer [10].
In this study, a tool for automated quantitative assess-
ment of Ki-67 expression is presented. The tool is
implemented within a previously described web-based
virtual microscopy platform [23]. The IHC quantifica-
tion method is evaluated by comparing the results with
visual assessment of Ki-67 expression in a comprehen-
sive series of breast cancer specimens. By linking the
clinicopathological data with related tissue samples, the
relationship between automated Ki-67 expression analy-
sis and survival is assessed.
Methods
Patients
The FinProg series consist of 2842 breast cancer patients
diagnosed during 1991 and 1992 within five geographical
regions of Finland. The regions cover half of the popula-
tion and the cases represent 53% of all breast cancers
diagnosed in Finland during this period. Clinical data
associated with subjects were extracted from the hospital
case records, hospital registries, the Finnish Cancer Reg-
istry, and Statistics Finland. The data comprises more
than 50 clinicopathological factors, including the histolo-
gical type and grade of breast cancer, the number of
metastatic and examined lymph nodes, primary tumour
size, tumour ER and PR content evaluated by immuno-
histochemistry in the TMA samples, treatment details,
and follow-up data. More than 50 pathologists performed
histological typing and grading of cancer at the time of
the diagnosis according to the World Health Organiza-
tion guidelines. The median follow-up time of subjects
included in the study was 9.5 years. Permission to use
clinical data and formalin-fixed, paraffin-embedded tis-
sues for research purposes was provided by the Ministry
of Social Affairs and Health, Finland (permission 123/08/
97). With reference to the large number of studied cases
the authorities granted permission to use tissue samples
without individual patient consent.
Exclusion criteria
Subjects diagnosed with ductal or lobular carcinoma in
situ were excluded from the study before statistical ana-
lyses as well as those who had distant metastases at the
time of the diagnosis, bilateral breast cancer, or other
malignancy than breast cancer in history, except basal
cell carcinoma or cervical carcinoma in situ. Since the
risk of dying from these last mentioned two malignant
diseases after diagnosis and proper treatment is exceed-
ingly small, the possible confounding effect on the survi-
val estimates was considered insignificant and not to
require exclusion of the subjects. A subject was also
excluded if no breast surgery was carried out. A single
subject may have been excluded for one or more rea-
sons. A consort diagram is provided in figure 1.
2842 patients with breast cancer
in FinProg database
DCIS n=203
Distant metastases present at 
diagnosis n=136
Bilateral breast cancer n=261
Other malignancy n=235
No breast surgery n=42
Tissue block not available
n=101
Tissue core not available or not 
representative n=597
1334 patients with
1648 tissue core images 
available for analysis
Excluded
Excluded
Excluded
2032
1931
Figure 1 Consort diagram.
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Preparation of tissue microarrays
Formalin-fixed, paraffin-embedded samples of the pri-
mary tumours (n = 1931) were collected and 1-4 tissue
cores (core diameter 0.6 mm) from each patient
assembled into tissue microarrays (TMAs, n = 23) as
described elsewhere [24]. Sections of 5 μm were cut and
processed for immunohistochemistry (IHC).
Immunohistochemistry (IHC)
Immunostaining for Ki-67 was done using a mouse
monoclonal antibody MM-1 (Novocastra Laboratories;
1:1,000 dilution) as previously described [25]. An evalu-
able Ki-67 staining was available in 1334 (69,1%) of the
1931 eligible cases with tumour tissue available for analy-
sis. The number of samples lost due to tissue processing
or with non-representative tissue spots was 597. The
extent of Ki-67 staining was assessed visually in 1292 of
the cases by one of the researchers (HS) under supervi-
sion of a single pathologist (JI) as part of a previous study
[25], counting the number of positive tumour cells and
classified into negative, moderate and high expression
with cut-off values at 0% and 20%. Immunostainings for
ER, PR, HER1, HER2, TP53, cyclooxygenase-2, KIT,
GATA-3 and CK 5/6 were also assessed as previously
reported [25]. Molecular subtypes were defined as lumi-
nal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or
PR+, HER2+), basal-like (ER-, PR-, HER2-, cytokeratin 5
+, and/or HER1+), HER2+/ER- (ER-, PR-, and HER2+),
and five-marker negative (negative for all markers) [25].
Sample digitization
Twenty-three TMA slides, with 2749 tissue spots includ-
ing duplicates, triplicates and quadruplicates, were digi-
tized with an automated whole-slide scanner (Mirax Scan,
Zeiss, Göttingen, Germany), using a 20× objective and a
DFW-X710 camera (Sony, Tokyo, Japan). The pixel
resolution was 0.26 micrometers per pixel. The virtual
slides were compressed to a wavelet file format (Enhanced
Compressed Wavelet, ECW, ER Mapper, Erdas Inc,
Atlanta, Georgia) with a conservative compression ratio of
1:5.
Virtual microscopy platform
The computer vision algorithm was integrated with a
previously described virtual microscopy platform [23,26],
which allows image analysis scripts to be run in a batch
mode on the server hosting the virtual slides. The com-
pressed virtual slides of the TMAs stained for Ki-67
analysis were uploaded to the web server equipped with
2 quad-core Intel Xeon processors and 16 GB of RAM.
TMA spot locations on the virtual slides were defined
by an annotation system in the virtual microscopy user
interface and linked to the corresponding clinical data.
Images of the TMA spots, 1634×1634 pixels in size,
were extracted from the virtual slides as separate image
files, exported into the computer vision algorithm, and
stored on the server for later manual inspection and
documentation purposes.
Computer vision algorithm
The computer vision algorithm (IhcJ) is depicted in figure
2. It utilizes the macro language of an image processing
and analysis software, ImageJ, which is open source and
available free of charge for multiple operating systems at
http://rsb.info.nih.gov/ij/. The IhcJ algorithm first divides
the acquired image of the IHC stained specimen in RGB
colour space into separate colour channels by a colour
deconvolution method [27]. The ImageJ plugin for colour
deconvolution has a built in vector for separating haema-
toxylin (H) and diaminobenzidine (DAB) stainings. After
colour deconvolution, H and DAB images are processed
separately. By using five random test samples stained for
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Mean intensity
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Figure 2 The IhcJ algorithm for automatic quantitative assessment of Ki-67 proliferation index.
Konsti et al. BMC Clinical Pathology 2011, 11:3
http://www.biomedcentral.com/1472-6890/11/3
Page 3 of 11
Ki-67, suitable threshold levels for H and DAB were deter-
mined. These thresholds were used on both H and DAB
images, respectively, and kept constant for the analysis of
the main image dataset. Thresholding creates binary
masks of H and DAB positive areas and the two areas may
overlap. Binary masks were merged into a single result
image. In the result image, the area of H-positive and
DAB-negative pixels is pseudocoloured with green colour.
The area of DAB-positive pixels regardless of H-status is
pseudocoloured with red colour. The background, where
both values are negative, is indicated with white colour.
The extent of staining is calculated as the total num-
ber of DAB-positive pixels divided by the union of the
total number of H-positive pixels and the total number
of DAB-positive pixels. The intensity of staining is cal-
culated from DAB-positive area, as a mean pixel value
of original DAB image. The mean intensity value is
scaled to range from 0 to 100 percent.
Statistical analysis
For statistical analyses, only the highest extent or inten-
sity of Ki-67 staining was considered if multiple evaluable
tissue cores were available for the same patient. Continu-
ous Ki-67 extent and intensity values generated by the
computer vision algorithm were grouped. There is no
consensus for cut-off values in the literature, some stu-
dies use arbitrary values, some median and some divide
data in tertiles [19,22]. In the current study we decided to
split the patient series into three approximately equally
sized groups according both to Ki-67 extent of staining
tertiles and intensity tertiles. For evaluation of agreement
between the visual and automated assessment of Ki-67
we also split the automated results into similar propor-
tions of low, moderate and high expression as for the
visual results. Frequency tables were analyzed using the
chi-square test. The agreement between the visual and
automated methods in the assessment of Ki-67 expres-
sion was estimated by percent-agreement and kappa-sta-
tistics. Since the categories of the variables are ordered as
described before, a linearly weighted kappa value was
used [28]. Life tables were calculated according to the
Kaplan-Meier method. Distant disease-free survival was
calculated from the date of the diagnosis to the date of
detection of metastases outside of the locoregional area
or to the date of death from breast cancer, if a patient
died of breast cancer without distant metastases. Patients
who died from an intercurrent disease were censored on
the date of death. Survival curves were compared with
the log-rank test. Multivariate survival analyses were
done with the Cox proportional hazards model, entering
the following covariates: automated assessment of Ki-67
extent of staining or visually assessed Ki-67 proliferation
index, method of tumour detection, tumour size in centi-
metres, number of metastatic lymph nodes, histological
grade, and age at diagnosis. The assumption of propor-
tional hazards was ascertained by assessment of log
minus log survival plots. All P values are two tailed.
Results
Automated Ki-67 expression assessment
A total number of 1648 TMA spot images from the
1334 subjects were analysed in 107 minutes. There were
251 subjects with duplicate, 21 with triplicate and 7
with quadruplicate cores among the readable cases. The
average analysis time for single TMA spot was 3.9 sec-
onds. The mean and median extent of staining for Ki-67
according to the computer vision analysis was 8.8% and
4.3% (range 0-95.3%) and the mean and median inten-
sity was 52.5% and 53.2% (range 33.9-67.0%). Sample
images are displayed in figure 3. For the purpose of sta-
tistical analysis, the patient series was split at tertiles
into groups according to the automated assessment of
Ki-67 extent of staining: 0 to 2.3 percent extent of stain-
ing was assigned to the low extent group, 2.4 to 6.3 per-
cent extent of staining to the moderate extent group
and 6.4 to 100 percent to the high extent group. For
automated assessment of Ki-67 intensity the tertile
thresholds were: low intensity group from 0 to 49.6 per-
cent, moderate intensity group from 49.7 to 56.6 per-
cent, and high intensity group from 56.7 to 100 percent.
Visual assessment of Ki-67
According to visual assessment of Ki-67 staining, 7.7%
of the patients were assigned to the negative expression
group, 55.7% to the moderate expression and 36.7% to
the high expression group.
Association of automated assessment of Ki-67 expression
with clinicopathological characteristics
When the patient series was split according to automated
assessment of Ki-67 extent of staining into similar size
groups as the visual Ki-67 results, 76% of the cases with
high visually assessed extent had high automatically
assessed extent, and none had low extent. Forty-six per-
cent of the cases with negative visually assessed extent
also had low automatically assessed extent, and only 2%
had high extent (table 1). The percentage agreement was
87% and weighted kappa value 0.57 (table 1).
For the main analysis, we examined the relationship
between automated assessment of Ki-67 expression and
clinicopathological variables by splitting the series
according to automated assessment of Ki-67 tertiles.
Patients younger than 35 years at the time of diagnosis
had a significantly higher extent of Ki-67 staining than
those diagnosed at a higher age (P = 0.0008) (table 2).
Cancers detected within mammography screenings had
lower automated assessment of Ki-67 extent than those
detected outside of screening (P = 0.0001). Increasing
Konsti et al. BMC Clinical Pathology 2011, 11:3
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primary tumour size is strongly associated with higher
Ki-67 extent of staining (P < 0.0001), as is increasing
histological grade (P < 0.0001). A higher number of
metastatic axillary lymph nodes also associates with
higher Ki-67 extent of staining (P = 0.01). There is a sig-
nificant difference in distribution of automated assess-
ment of Ki-67 extent among different histological types
of breast cancer (P < 0.0001): in ductal carcinomas,
higher extent is more frequent, whereas lower extent of
Ki-67 staining predominates in lobular carcinomas. For
molecular markers, high automated assessment of Ki-67
extent is strongly associated (all with P < 0.0001) with
negative ER and PR expression, positive HER2 amplifi-
cation and expression and high p53 expression. When
molecular subtypes are considered, only Luminal A is
associated with low automated assessment of Ki-67
extent, while other molecular subtypes tend to have
higher Ki-67 extent of staining (P < 0.0001).
Uni- and multivariate analyses of distant disease-free
survival
Increasing extent of Ki-67 staining as determined by
image analysis is significantly associated with a decrease
in distant disease-free survival (DDFS; figure 4a).
Patients with a moderate automated assessment of Ki-67
extent of staining have a hazard ratio of 1.77 (95% CI
1.31-2.37) for distant recurrence, and those with the
high automated assessment of extent of staining have a
hazard ratio of 2.34 (95% CI 1.76-3.10), as compared to
patients with a low automated assessment of Ki-67
extent of staining (table 3). The 5- and 10-year DDFS
for the low Ki-67 extent group were 89% and 81%,
respectively (table 4). DDFS for the moderate automated
assessment of Ki-67 extent of staining group were 77%
and 71%, and for the high automated assessment of
Ki-67 extent group 69% and 64%.
In subgroup analysis according to histological grade,
patients with grade 1 tumours and moderate automated
assessment of Ki-67 extent had a hazard ratio of 1.05
(95% CI 0.35-3.22) and patients with high automated
assessment of Ki-67 extent a hazard ratio of 4.63 (95%
Table 1 Agreement between automatic and visual
assessment of Ki-67 proliferation index (Kappa statistics,
linear weights, Percentage agreement 87%, Kappa 0.57)
Visual
Negative Moderate High Total
Low 46 53 0 99
Automatic Moderate 51 554 114 719
High 2 112 360 474
Total 99 719 474 1292
Figure 3 Sample images of variable area of Ki-67 staining in FinProg series. Low extent of staining (a), moderate extent of staining (b),
high extent of staining (c), and corresponding result images from IhcJ macro (d, e, f).
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Table 2 Association of automated assessment of Ki-67 extent of staining with clinicopathological characteristics
Characteristic Automated assessment of Ki-67 extent of staining P
Low N (%) Moderate N (%) High N (%)
All tissue samples (N = 1334) * 406 (30) 446 (33) 482 (36)
Ki-67 expression (visual)
High 13 (3) 102 (22) 359 (76) < 0.0001
Moderate 293 (41) 314 (44) 112 (16)
Negative 82 (83) 15 (15) 2 (2)
Not available 18 (43) 15 (36) 9 (21)
Age at diagnosis (y)
< 35 2 (6) 13 (36) 21 (58) 0.0008
35-50 101 (28) 120 (33) 141 (39)
50-65 160 (36) 133 (30) 149 (34)
>65 143 (29) 180 (36) 171 (35)
Method of detection
Mammography screening 102 (41) 81 (33) 66 (27) 0.0001
Other 298 (28) 355 (34) 403 (38)
Not available 6 (21) 10 (34) 13 (45)
Primary tumour diameter (cm)
< 0.5 8 (44) 8 (44) 2 (11) < 0.0001
0.5-1 82 (42) 66 (34) 49 (25)
1-2 182 (34) 180 (34) 172 (32)
2-5 104 (22) 156 (33) 212 (45)
> 5 13 (24) 14 (25) 28 (51)
Not available 17 (29) 22 (38) 19 (33)
No. of positive axillary nodes
0 276 (35) 253 (32) 264 (33) 0.0142
1-3 80 (27) 98 (33) 119 (40)
4-9 26 (23) 45 (40) 41 (37)
≥ 10 5 (16) 11 (35) 15 (48)
Not available 19 (19) 39 (39) 43 (43
Histological grade
1 118 (52) 73 (32) 37 (16) < 0.0001
2 122 (26) 184 (39) 171 (36)
3 34 (12) 67 (23) 188 (65)
Not available 132 (39) 122 (36) 86 (25)
Histological type
Ductal 275 (27) 342 (34) 402 (40) < 0.0001
Lobular 87 (46) 67 (35) 36 (19)
Special 44 (35) 37 (30) 44 (35)
ER expression
Positive 301 (35) 324 (38) 234 (27) < 0.0001
Negative 69 (17) 102 (26) 228 (57)
Not available 36 (47) 20 (26) 20 (26)
PR expression
Positive 254 (37) 270 (39) 171 (25) < 0.0001
Negative 122 (21) 151 (27) 295 (52)
Not available 30 (42) 25 (35) 16 (23)
HER2 amplification
Positive 34 (14) 75 (31) 134 (55) < 0.0001
Negative 331 (33) 333 (34) 327 (33)
Not available 41 (41) 38 (38) 21 (21)
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CI 1.83-11.75), as compared to patients with low auto-
mated assessment of Ki-67 extent. In patients with
grade 2 tumours, the corresponding figures were 1.51
(95% CI 0.95-2.42) and 1.99 (95% CI 1.26-3.15). In the
grade 3 subgroup, the results were 1.37 (95% CI 0.69-
2.73) and 0.97 (95% CI 0.51-1.84). In the subgroup of
patients with ductal breast cancer, the figures were 1.83
(95% CI 1.30-2.58) and 2.30 (95% CI 1.66-3.18), and in
the lobular carcinoma subgroup, the corresponding
hazard ratios were 1.40 (95% CI 0.67-2.93) and 2.29
(95% CI 1.06-4.95).
When extent of Ki-67 staining was determined
visually, patients with a moderate visually assessed Ki-67
expression had a hazard ratio of 1.41 (95% CI 0.83-2.39)
for distant recurrence, and those with a high visually
assessed Ki-67 expression had a hazard ratio of 2.58
(95% CI 1.52-4.37), as compared to patients with a nega-
tive visually assessed Ki-67 expression.
For computer determined Ki-67 intensities, no statisti-
cally significant difference was observed between low
and moderate intensity groups (figure 4b). The high
intensity group was associated with significantly less
favourable distant disease-free survival (HR = 1.34, 95%
CI 1.04-1.73) compared to the low intensity group.
In a multivariate survival analysis, adjusted for tumour
size, the number of positive lymph nodes, histological
grade, method of detection and age at diagnosis, patients
with a moderate automated assessment of Ki-67 extent
of staining had a hazard ratio of 1.62 (95% CI 1.10-2.39)
and those with high Ki-67 extent a hazard ratio of 1.73
(95% CI 1.19-2.51), compared to patients with low auto-
mated assessment of Ki-67 extent of staining (table 3).
The visually determined Ki-67 expression was not
retained as a significant prognostic factor if entered
instead of the computer determined Ki-67 extent in the
same multivariate model (table 3). Computer deter-
mined Ki-67 intensity was not significantly associated
with DDFS in the multivariate model.
Discussion
In the current report we describe the integration of an
open source image analysis tool with a virtual micro-
scopy platform. Computer determined extent of immu-
nohistochemical staining of the extensively studied
biomarker Ki-67 shows prognostic value comparable to
visually assessed Ki-67 in a comprehensive series of
patients with breast cancer.
The automated assessment of Ki-67 extent of staining
was significantly associated with all the examined clinico-
pathological characteristics, including tumour size, num-
ber of positive lymph nodes, histological type and grade,
oestrogen and progesterone receptor status, age at diagno-
sis, method of tumour detection, as well as molecular sub-
types. These findings are in good agreement with
previously reported results on the association between Ki-
67 expression and clinicopathological factors [25,29]. The
comparison of visual and automated assessment of Ki-67
expression showed only moderate agreement. The human
observer may exclude non-tumour or stromal areas in the
sample more effectively than the image analysis algorithm,
which may explain part of the discrepancies. Also, the
image analysis algorithm can include artefacts and staining
errors. On the other hand, the human interpretation can
vary due to the visual evaluation being done on several
Table 2 Association of automated assessment of Ki-67 extent of staining with clinicopathological characteristics
(Continued)
HER2 expression
Positive 26 (13) 60 (29) 121 (58) < 0.0001
Negative 333 (33) 340 (34) 324 (33)
Not available 47 (36) 46 (35) 37 (28)
p53 expression
High 16 (7) 50 (22) 158 (71) < 0.0001
Moderate 98 (27) 135 (37) 129 (36)
Low 222 (39) 196 (34) 155 (27)
Not available 70 (40) 65 (37) 40 (23)
Molecular subtype
Basal 11 (12) 15 (16) 69 (73) < 0.0001
HER2+/HR- 14 (12) 33 (28) 70 (60)
Luminal A 291 (38) 288 (37) 191 (25)
Luminal B 19 (16) 37 (32) 60 (52)
Five-marker negative 8 (19) 6 (14) 28 (67)
Unclassified 9 (16) 18 (32) 29 (52)
Not available 54 (39) 49 (36) 35 (25)
* due to ties the number of samples in each tertile is not equal.
Konsti et al. BMC Clinical Pathology 2011, 11:3
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separate occasions. Visual thresholds may change between
scoring sessions because of altered microscopy settings or
reference spots with varying stain intensity. The observed
variability between visual and automated methods mostly
occurred between adjacent groups, only 2 patients with
negative visual score were in the automatically assessed
high extent group, and none of the patients with high
visual score were classified by the automated analysis into
the low extent group. The two totally discrepant cases
were caused by partially folded TMA spot and falsely dyed
spot. In general, automated method underestimated the
extent of staining in samples with high stromal content or
with just a few strongly positive tumor nuclei. The main
causes for too high automated scores were out-of-focus
samples, debris on the glass slide or positive staining of
the tumor cytoplasm.
The analysis of distant disease-free survival shows that
the automated assessment of Ki-67 extent of staining is
a significant predictor of outcome in breast cancer.
When compared to low extent of Ki-67 staining,
moderate and high extent of staining is associated with
hazard ratios of 1.77 and 2.34 for distant recurrence
during the follow-up period. These results are in line
with previous meta-analyses, where the pooled hazard
ratios for disease-free survival (DFS) associated visually
determined Ki-67 overexpression have been 1.93-2.18
[19,22].
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Figure 4 Distant disease-free survival (Kaplan-Meier curves,
whole dataset). by the grouped Ki-67 extent of stainings (a), and
by the grouped Ki-67 staining intensities (b).
Table 3 Cox uni- and multivariate distant disease-free
survival analyses
Covariate (univariate analyses) HR 95% CI P
Ki-67 (Automated assessment of extent of
staining)
Low 1.00
Moderate 1.77 1.31-2.37 <0.0001
High 2.34 1.76-3.10 <0.0001
Ki-67 (Visually assessed proliferation index)
Negative 1.00
Moderate 1.41 0.83-2.39 0.207
High 2.58 1.52-4.37 <0.0001
Covariate (multivariate analyses) HR 95% CI P
Ki-67 (Automated assessment of extent of
staining)
Low 1.00
Moderate 1.62 1.10-2.39 0.014
High 1.73 1.19-2.51 0.004
Tumour size* 1.23 1.14-1.34 <0.0001
No. of positive axillary lymph nodes† 1.14 1.11-1.18 <0.0001
Histological grade (grade 3 or 2 vs. 1) 2.17 1.36-3.47 0.001
Detection at mammography screening 0.50 0.32-0.78 0.002
Age at diagnosis
< 50 1.00
>50 1.18 0.90-1.55 0.221
Ki-67 (Visually assessed proliferation index)
Negative 1.00
Moderate 0.71 0.37-1.38 0.311
High 1.03 0.53-2.01 0.920
Tumour size* 1.25 1.15-1.35 <0.0001
No. of positive axillary lymph nodes† 1.14 1.11-1.18 <0.0001
Histological grade (grade 3 or 2 vs. 1) 2.36 1.46-3.80 <0.0001
Detection at mammography screening 0.47 0.30-0.74 0.001
Age at diagnosis
< 50 1.00
>50 1.20 0.92-1.58 0.185
*Hazard provided per one centimetre of the longest diameter of the tumour
†Hazard provided per one metastatic node
Table 4 5- and 10-year survival
Automated assessment
of Ki-67
extent of staining
N 5-year survival
(95% CI)
10-year survival
(95% CI)
Low 334 89 % (85%-92%) 81% (77%-85%)
Moderate 303 77% (72%-80%) 71% (66%-75%)
High 305 69% (65%-73%) 64% (60%-69%)
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When other variables are taken into account in the
multivariate survival analysis, the automated assessment
of Ki-67 extent of staining remains as a significant prog-
nostic factor with hazard ratios of 1.62 and 1.73 for
moderate and high extent of staining groups, respec-
tively. Thus, the automated assessment of Ki-67 extent
of staining is an independent predictor of patient out-
come after adjustment for established clinicopathological
factors. Also this is in agreement with results of meta-
analyses, where a pooled DFS hazard ratio for Ki-67
overexpression in multivariate analysis was reported to
be 1.76-1.84 [19,22]. In the current study, the visually
determined Ki-67 failed to reach significance in the mul-
tivariate model, possibly due to previously discussed
variability in human observer assessment. The auto-
mated Ki-67 intensity assessment was of limited prog-
nostic value. This could partly be explained by the
difficulties in quantification of the diaminobenzidine
staining, due to a previously described non-linear rela-
tionship between the amount of antigen and the staining
intensity [30].
The strengths of this study include that we analysed
a large unselected breast cancer series with long fol-
low-up period. The software and algorithms that were
utilized are open source and integrated into a virtual
microscopy platform. They could be made freely avail-
able as a software service on a public web site. Exam-
ples of this approach have recently been published
and represent a promising methodology for standardi-
zation of quantitative immunostaining assessment and
fluorescence in situ hybridization (FISH) signal count-
ing [17,26]. This method could also be useful tool in
routine breast cancer diagnostic pathology of prognos-
tic and predictive factors. Even though the usage of
TMA slides in this domain has shown promising
results [31], these factors are mainly assessed from
whole slide sections. Our approach can, however, be
applied also to whole slide sections via either taking
digital snapshots of regions of interest, or in case of
virtual whole slides, the area to be analyzed can be
selected manually.
A weakness of the algorithm proposed in our study is
the need for manual adjustment of threshold levels
before starting the batch analysis. A constant threshold
level for the image analysis algorithm seems acceptable
if similar tissue processing and staining protocols are
applied throughout the whole specimen series, as in the
current study. Another weakness of the current compu-
ter vision approach is that also stromal components of
tissue samples were included in the automated assess-
ment. This affects the distribution of the extent of stain-
ing as compared to studies that have excluded tumour
stroma and calculated the proportion of stained cells in
the tumour parenchyma only. An approach that does
not exclude stroma might be acceptable for analysis of
tissue microarrays that have been constructed to mainly
contain tumour tissue. However, also in the TMAs the
ratio of stroma to tumour epithelium can vary according
to tumour grade and histological type, which can affect
the extent of staining. Therefore we performed sub-
group analysis according to histological grade and type,
as well as adjusted for these possible confounders in a
multivariate survival model. The automated assessment
of Ki-67 extent of staining was a significant prognostic
factor in all subgroups, except for in the group of
patients with poorly differentiated tumours. This is in
line with previous results showing a lack of prognostic
value of Ki-67 in grade 3 tumours [32]. For analysis of
individual samples and whole slide surgical tumour sam-
ples within a routine diagnostic setting, an image analy-
sis method for excluding stroma would be needed.
Examples of such method have been described in com-
mercial systems [15,16]. Also, a method that segments
and analyses tumour nuclei only might be better suited
for the Ki-67 antigen, which mainly is expressed in the
cell nuclei. However, algorithms that segment tumour
nuclei require an optimal nuclear counterstain, which
can be hard to achieve in practice. On the other hand, a
recent study showed that also cytoplasmic and membra-
nous expression of Ki-67 is of prognostic value in breast
cancer [33].
Conclusions
We conclude that the extent of Ki-67 staining deter-
mined by automated image analysis algorithm is an
independent predictor of survival in breast cancer based
on multivariate survival analysis. In univariate analysis,
the automated assessment of Ki-67 extent of staining
yields comparable results to the visual Ki-67 assessment.
The current approach could be utilized in screening of
prognostic biomarkers in large series of tissue microar-
rays, by integration with whole slide microscopy imaging
and virtual microscopy.
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